The FDA approved Merck’s Welireg (belzutifan) plus Eisai-partnered Lenvima (lenvatinib) for adults with advanced clear-cell renal cell carcinoma after prior PD-(L)1 therapy, based on the Phase III LITESPARK-011 trial in 747 patients. The combo improved median progression-free survival to 14.6 months vs. 10.6 months with cabozantinib and raised objective response rate to 53% vs. 40%, though final overall survival was not statistically significant.

Why It Matters To Oncology

• Welireg moves earlier in advanced RCC, expanding beyond its original 2023 use after both PD-(L)1 and VEGF-targeted therapy.

• The approval adds a post-immunotherapy option pairing HIF-2α inhibition with VEGF blockade in clear-cell disease.

• For drug discovery watchers, the readout further validates HIF-2α as a clinically actionable target in kidney cancer.

The Financials

• Merck broadens Welireg’s commercial reach just three months after its adjuvant approval with pembrolizumab.

• The new label strengthens Merck’s RCC franchise while also benefiting partner Eisai through Lenvima’s use in combination.

• Competitive pressure remains: the regimen beat Exelixis’ Cabometyx on progression-free survival and response rate, but not on statistically significant overall survival.

What They're Saying

• Michael Atkins of Georgetown Lombardi told FirstWord after the June adjuvant approval that many patients may not receive Welireg later in metastatic disease if they have already had it earlier.

• That dynamic could narrow the real-world second-line pool for Welireg-Lenvima despite the new FDA clearance.

What's Next

• Clinicians will watch how prior adjuvant Welireg exposure affects sequencing decisions in metastatic RCC.

• Uptake may hinge on whether physicians prioritize the progression-free survival benefit despite a non-significant overall survival result.

• Further follow-up and real-world data should clarify where Welireg-based combinations fit against other RCC standards.